section name header

Quick Reference

Benign Prostatic Hyperplasia - Quick Reference

  • This is a Quick Reference article. See also the main article Benign prostatic hyperplasia Benign Prostatic Hyperplasia.

Examining the patient

Drug therapy

  • Watchul waiting is sufficient, if the symptoms are mild (IPSS < 8).
  • If the prostate size is < 30 ml and PSA is < 1.5 µg/l, first choice is an alpha-1 blocker: tamsulosin, alfuzosin, doxazosin or terazosin.
  • If the prostate is clearly enlarged or PSA is > 1.5 µg/l, a 5-alpha-reductase inhibitor (finasteride or dutasteride) or an alpha-1 blocker can be used.
  • The combination of an alpha blocker and a 5-alpha-reductase inhibitor relieves symptoms more efficiently than either drug alone.
  • Phosphodiesterase 5 inhibitors are particularly suitable for patients suffering from mild to moderate urinary symptoms and who concomitantly are in need of treatment for erectile dysfunction.

Indications for referral to a urologist

  • Age under 50 years
  • Suspicious finding at palpation of the prostate (nodularity or a hard area)
  • The following abnormalities in PSA concentrations:
    • PSA > 10 µg/l, or > 3 µg/l in patients under 65 years of age
    • PSA increase > 0.75 µg/l/year
    • Total PSA in the range 4-10 µg/l and free PSA fraction < 15 % of total PSA
  • Urinary retention (first aid: suprapubic cystostomy [video Suprapubic Cystostomy] or catheterization), overflow incontinence, or residual urine exceeding 400 ml despite drug therapy
  • Pain associated with difficulty in urination
  • Haematuria

Follow-up

  • Inform the patient that he should contact the doctor if the symptoms get worse.
  • Test for creatinine, PSA and (if indicated) residual urine at 6-12-month intervals.
  • PSA concentration should decrease during finasteride treatment.